Total
0
Shares
Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PharmAust has reopened its Phase 2 clinical trials in dogs with cancer using its newly formulated tablet
  • Its GMP monepantel tablets are manufactured and remain on track for imminent delivery
  • Phase 2 is expected to finish in August/September this year

PharmAust recieved approval from NSW Animal Care & Ethics Committee to reopen Phase 2 clinical trials in dogs with cancer.

PharmAust had previously received ethics approval for its anti-cancer program in dogs however, even though it demonstrated strong signs of anti-cancer effectiveness the formulation was inedible and could not be used effectively.

For phase 2 PharmAust developed a taste-neutral tablet.

After reviewing the application the Ethics Committee approved the trial for both long-term and short-term studies. The effectiveness is measured by achieving stable disease, progression-free survival or shrinking of tumours.

PharmAust has also announced that the manufacturing of the new tablet is also complete. The shelf-life tests will be finalised midway through August and are required before the tablet can be distributed.

Chief Scientific Officer of PharmAust Dr Richard Mollard expects delivery to happen soon.

“PharmAust anticipates the delivery of the tablets from the USA in August/September and then recruitment can commence for the Phase 2 trials shortly thereafter,” he said.

Its GMP monepantel (MPL) tablets are an oral aminoacetonitrile compound that modulates the mTOR pathways, which is a key driver in many types of cancers. With more than 80 per cent of dog owners using drugs to treat their animals PharmAust is evaluating its MPL for treatment of cancers in dogs and other companion animals.

PharmAust shares are remaining steady at 5 cents with a market cap of $14.01 million.

PAA by the numbers
More From The Market Herald
Race Oncology (ASX:RAC) - CEO, Phillip Lynch

" Race Oncology (ASX:RAC) posts nominal decline in cash

Race Oncology (RAC) has posted a nominal decline in cash and equivalents as of 30 September 2021 to $8.94 million, down from $9.32...
Prescient Therapeutics (ASX:PTX) - Managing Director and CEO, Steven Yatomi Clarke

" Prescient Therapeutics (ASX:PTX) logs timely progress across anti-cancer programs in Q3

Prescient Therapeutics (PTX) says it is poised to reach value-adding milestones across its anti-cancer programs after wrapping up the September quarter with $14.8...
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) highlights trial progress in September quarterly

Neuren Pharmaceuticals (NEU) has released its September quarterly report, highlighting the progress with its upcoming clinical trials.

" Invion (ASX:IVX) sees complete regression of tumours in breast cancer trial

Invion (IVX) shares have soared following its latest trial results, demonstrating a complete regression in tumours following in vivo treatment.